Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.
Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN β-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.
ACTRIMS 2017 Forum: MS Treatment Clinical Trials
Clinical Follow-up of 411 Patients with Multiple Sclerosis Ten Years after Mitoxantrone Treatment Abstract link.
What is the sustained effect of mitoxantrone in patients with relapsing or progressive MS?
Mitoxantrone offered patients a sustained (albeit reduced at 5 years) effect at 10 years; treatment was more likely to benefit less active and disabled relapsing patients.
NEDA Analysis by Epoch in Patients with Relapsing Multiple Sclerosis Treated with Ocrelizumab: Results from the OPERA I and OPERA II Phase III Studies Abstract link.
How many patients with relapsing MS had no evidence of disease activity (NEDA) on ocrelizumab vs interferon beta 1-a (IFN β-1a)?
Patients on ocrelizumab were much more likely to achieve NEDA than patients on IFN β-1a.
Evaluation of No Evidence of Progression (NEP) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial Abstract link.
What proportion of patients with PPMS achieved no evidence of progression (NEP) on ocrelizumab?
Compared to placebo, ocrelizumab resulted in an increased proportion (47%) of patients with NEP at 120 weeks compared with placebo.
